Methotrexate treatment for unruptured ectopic pregnancy is MOST likely to fail (require surgical intervention) in which of the following clinical scenarios?

• A Serum β-hCG 12,000 IU/L, adnexal mass 4.5 cm, cardiac activity present on ultrasound ✓
• B Serum β-hCG 3500 IU/L, adnexal mass 2.5 cm, no cardiac activity on ultrasound
• C Serum β-hCG 1800 IU/L, adnexal mass 2 cm, asymptomatic patient
• D Serum β-hCG 4000 IU/L after a previously failed IVF cycle, no cardiac activity

Explanation

Methotrexate failure predictors include: serum β-hCG >5000 IU/L (strongest predictor), adnexal mass >3.5 cm, and presence of fetal cardiac activity. This patient has β-hCG 12,000 IU/L (very high), mass 4.5 cm, and cardiac activity — meeting all three major failure predictors. Such cases should be considered for primary surgical management (salpingectomy) rather than medical therapy, or at minimum require very close monitoring with multi-dose protocol. The RCOG and ACOG guidelines consider cardiac activity as a relative contraindication to single-dose methotrexate.

Reference: Williams Obstetrics, 26th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.